



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to:
MS: RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 28, 2006

Signature:

Rochelle Capobianco
(Rochelle Capobianco)

Docket No.: VOS-012
0107070.00113US1)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Oliver Bruestle	Confirmation No.:	7106
Application No.:	09/581890	Art Unit:	1632
Filed:	August 28, 2000	Examiner:	A. M. Falk
Title:	NEURAL PRECURSOR CELLS, METHOD FOR THE PRODUCTION AND USE THEREOF IN NEURAL DEFECT THERAPY		

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination. No fee is required.

Applicants note that only the abstract is provided for Csiza, et al., "Myelin Deficiency (md)" (1979). A complete copy of the reference will be provided subsequently.

Furthermore, the best available copy of Duncan, et al., "Repair of Myelin Disease: Strategies and Progress in Animal Models", Molecular Medicine Today, December 1997, is enclosed herewith.


Application No.: 09/581890

Docket No.: VOS-012 (107070.113US1)

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: April 28, 2006

A handwritten signature in black ink, appearing to read "Ann-Louise Kerner", written over a horizontal line.

Ann-Louise Kerner, Ph.D.

Registration No.: 33,523

Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000 (telephone)
(617) 526-5000 (facsimile)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/581890-Conf. #7106
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	August 28, 2000
				First Named Inventor	Oliver Bruestle
				Art Unit	1632
				Examiner Name	A. M. Falk
Sheet	1	of	1	Attorney Docket Number	VOS-012 (0107070.00113US1)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Csiza, et al., "Myelin Deficiency (md)" (1979), (Abstract Only)	
	CB	Duncan, et al., "Repair of Myelin Disease: Strategies and Progress in Animal Models", Molecular Medicine Today, December 1997	
	CC	Koeppen, et al., "Defective Biosynthesis of Proteolipid Protein in Pelizaeus-Merzbacher Disease", Annals of Neurology, 21:159-170, 1987	
	CD	Lazzarini, Myelin Biology and Disorders 2, Elsevier Academic Press, pp. 1130, 2004	
	CE	Nakagawa, et al., "Roles of Cell-Autonomous Mechanisms for Differential Expression of Region-Specific Transcription Factors in Neuroepithelial Cells", Development, Vol. 122, pp. 2449-2464, 1996	
	CF	Ostenfeld, et al., "Regional Specification of Rodent and Human Neurospheres", Developmental Brain Research, Vol. 134, pp. 43-55, 2002	
	CG	Reynolds, et al., "Clonal and Population Analyses Demonstrate That an EGF-Responsive Mammalian Embryonic CNS Precursor is a Stem Cell", Developmental Biology, Vol. 175, pp. 1-13, 1996	
	CH	Svendsen, et al., "Human Neural Stem Cells: Isolation, Expansion and Transplantation", Brain Pathology, Vol. 9, pp. 499-513, 1999	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

5632942